Especially, the gallbladder carcinoma patients Nu-IL4Rα-positive tumors had a 3.379-fold (95% CI; 1.825–6.254) greater risk in OS analysis and a 2.919-fold (95% CI; 1.622–5.253) greater risk in RFS analysis compared with the patients with negative for Nu-IL4Rα (Table 3). This evidence concerns the gene IL4R and gallbladder carcinoma.